Analysis of licensed pharmaceutical cannabis manufacturing across Europe — facility types, GMP certification status, product categories, capacity trends and the competitive dynamics shaping the European supply landscape.
Enter your email to receive the complete formatted PDF.
The European pharmaceutical cannabis manufacturing landscape in 2026 is characterised by significant capacity investment, increasing regulatory scrutiny and early signs of commercial consolidation. This publication analyses the structure of the European supply side — who manufactures, what they produce, how they are regulated and where the competitive dynamics are heading.
European pharmaceutical cannabis manufacturing operates across four primary facility types:
Facilities that cultivate cannabis under GACP, process it under EU GMP (extraction, purification, formulation) and hold both GACP and GMP licences. These are the most complex to establish and operate but provide full supply chain control and the highest margins.
Vertically integrated facilities are concentrated in Portugal, Greece and Denmark, where the combination of cultivation climate (or controlled indoor conditions), regulatory framework and proximity to the German market create favourable conditions.
Facilities that import GACP-certified cannabis starting material and process it under EU GMP. These operators are typically faster to GMP certification (facility qualification is simpler without cultivation infrastructure) but are dependent on external GACP supply chains.
Facilities that formulate and fill finished pharmaceutical cannabis products (oils, capsules, oral solutions) from GMP-certified cannabis extract or API supplied by upstream processors. These operators require pharmaceutical manufacturing expertise but may not require cannabis cultivation or extraction capability.
GMP-certified contract manufacturers (CMOs) that provide cannabis processing and/or formulation services to brand owners who do not have their own manufacturing capability. The emergence of cannabis-experienced CMOs in Europe represents a significant structural development — it lowers the barrier to market entry for cannabis brands and allows faster product launch without capital investment in manufacturing infrastructure.
EU GMP certification for cannabis manufacturing is issued by national competent authorities and mutually recognised across EU member states through the EMA's EudraGMDP database. A GMP certificate issued by Infarmed (Portugal) is recognised in Germany without additional inspection.
The EudraGMDP database is publicly searchable and provides the most reliable publicly available data on EU GMP-certified cannabis facilities. As of July 2026, EudraGMDP lists approximately 25–35 EU GMP certificates relevant to cannabis manufacturing across European jurisdictions — a figure that has grown significantly from fewer than 10 in 2020.
Many more facilities are at various stages of GMP implementation — having received manufacturing licences but not yet having completed facility qualification, validation programmes and initial GMP inspection. The pipeline of facilities approaching GMP certification is substantial, and the rate of new certifications is expected to remain high through 2027.
European GMP cannabis production covers three primary product categories:
| Category | Product examples | Regulatory pathway | Primary market |
|---|---|---|---|
| Cannabis flower | Standardised dried flower for vaporisation or pharmacy preparation | Herbal medicinal product or magistral starting material | Germany, Netherlands, Czech Republic |
| Cannabis extracts/oils | Full-spectrum oil, CBD oil, THC/CBD oil drops | Herbal preparation or finished medicinal product | Germany, UK, Poland, all European markets |
| Finished pharmaceutical preparations | Oral solutions, capsules, sublingual sprays | Authorised medicinal product (e.g. Sativex, Epidiolex) or magistral preparation | All markets with authorised products |
Entry of Colombian, South African and Lesotho producers into the European market — particularly the German market — has introduced significant price competition at the cannabis flower level. Colombian producers in particular have demonstrated the ability to supply EU GMP-certified flower at prices substantially below European domestic production costs.
This creates differentiation pressure on European producers — competing on price alone against low-cost international supply is not a sustainable strategy. European manufacturers are increasingly differentiating on quality consistency, regulatory relationships, supply security and product innovation.
Smaller European cannabis manufacturers — particularly those with single-product, single-market strategies — face increasing margin pressure. The costs of maintaining EU GMP compliance (ongoing qualification, environmental monitoring, quality system maintenance, regulatory affairs) are largely fixed costs that are more easily absorbed by larger, multi-product operations.
ECI expects consolidation among European cannabis manufacturers to accelerate through 2026–2027, with strategic acquisitions of qualified manufacturing assets by larger cannabis groups, pharmaceutical companies and investors seeking quality-assured EU supply chains.
The growth of cannabis-experienced CMOs represents one of the most significant structural developments in the European market. CMO availability lowers barriers to entry, allows brand-led cannabis companies to launch products without manufacturing investment and enables faster route to market for new product concepts.
European cannabis manufacturers who will thrive through 2027 share common characteristics: EU GMP certification across multiple product types; established regulatory relationships with BfArM and other national authorities; diversified market exposure across multiple European countries; product portfolio extending beyond commodity cannabis flower; and quality systems robust enough to withstand increasing inspection scrutiny.
Manufacturers who are at risk are those with single-product, single-market exposure; those whose GMP systems have not been updated to reflect the 2022 Annex 1 revision; and those competing primarily on price in commodity product categories against lower-cost international supply.
Subscribe for new publications monthly.